BR112019003579A2 - Composições de ribosídeo de nicotinamida e pterostilbeno e métodos para o tratamento dedistúrbios neurodegenerativos - Google Patents

Composições de ribosídeo de nicotinamida e pterostilbeno e métodos para o tratamento dedistúrbios neurodegenerativos

Info

Publication number
BR112019003579A2
BR112019003579A2 BR112019003579-6A BR112019003579A BR112019003579A2 BR 112019003579 A2 BR112019003579 A2 BR 112019003579A2 BR 112019003579 A BR112019003579 A BR 112019003579A BR 112019003579 A2 BR112019003579 A2 BR 112019003579A2
Authority
BR
Brazil
Prior art keywords
nicotinamide
compositions
neurodegenerative disorders
methods
riboside
Prior art date
Application number
BR112019003579-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Alexander Marcotulli Eric
Antonio Alminana Daniel
Original Assignee
Elysium Health, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elysium Health, Inc. filed Critical Elysium Health, Inc.
Publication of BR112019003579A2 publication Critical patent/BR112019003579A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
BR112019003579-6A 2016-08-22 2017-08-22 Composições de ribosídeo de nicotinamida e pterostilbeno e métodos para o tratamento dedistúrbios neurodegenerativos BR112019003579A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662378053P 2016-08-22 2016-08-22
US62/378,053 2016-08-22
PCT/US2017/047979 WO2018039207A1 (en) 2016-08-22 2017-08-22 Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
BR112019003579A2 true BR112019003579A2 (pt) 2019-05-21

Family

ID=61246253

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019003579-6A BR112019003579A2 (pt) 2016-08-22 2017-08-22 Composições de ribosídeo de nicotinamida e pterostilbeno e métodos para o tratamento dedistúrbios neurodegenerativos

Country Status (12)

Country Link
US (2) US11260069B2 (enExample)
EP (1) EP3500267A4 (enExample)
JP (1) JP7132907B2 (enExample)
KR (1) KR20190046895A (enExample)
CN (2) CN109982706A (enExample)
AU (1) AU2017316614B2 (enExample)
BR (1) BR112019003579A2 (enExample)
CA (1) CA3034673A1 (enExample)
MX (1) MX2019002211A (enExample)
RU (1) RU2019108100A (enExample)
WO (1) WO2018039207A1 (enExample)
ZA (1) ZA201901536B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7132907B2 (ja) 2016-08-22 2022-09-07 エリジウム・ヘルス・インコーポレイテッド ニコチンアミドリボシド及びプテロスチルベン組成物及び神経変性障害の治療方法
EP3624808A4 (en) * 2017-05-18 2021-03-03 Elysium Health, Inc. PROCEDURES AND COMPOSITIONS FOR IMPROVED SLEEP
US11286274B2 (en) 2017-06-19 2022-03-29 Mitopower Llc Nicotinamide riboside derivatives and their uses
CA3108015A1 (en) 2017-07-28 2019-01-31 Centers For Age Control, Inc. Compositions and methods for preventing and reversing aspects of aging
CN112955150A (zh) * 2018-10-19 2021-06-11 达萨玛治疗公司 与nad+或nad+前体组合的sarm1抑制剂
WO2020102326A1 (en) * 2018-11-13 2020-05-22 Elysium Health, Inc Methods for determining and increasing nad levels
WO2020131578A2 (en) 2018-12-17 2020-06-25 Mitopower Llc Nicotinyl riboside compounds and their uses
JP7580380B2 (ja) * 2019-02-26 2024-11-11 ウニベルシタット デ バレンシア―エストゥディ ジェネラル 運動ニューロン疾患を処置するための方法及び組成物
CN110812365A (zh) * 2019-11-07 2020-02-21 明特奇点医疗科技（北京）有限公司 一种组合物及其制备方法与制剂
CN111838669B (zh) * 2020-08-07 2022-11-29 四川大学华西医院 治疗改善易损脏器的纳米组合物、制剂及制备方法和用途
EP4029496A1 (en) * 2021-01-18 2022-07-20 Universitat de València Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases
EP4079311B1 (en) 2021-04-20 2025-10-01 Nuvamid SA Nmn and derivatives for use in the treatment of depression and/or anxiety in patients having a form of parkinsonism
WO2022269064A1 (en) * 2021-06-24 2022-12-29 Vestlandets Innovasjonsselskap As (Vis) Nad-augmentation therapy for parkinson's disease
DK4284387T3 (da) * 2021-06-24 2024-09-02 Vestlandets Innovasjonsselskap As Vis Nad-forstærkelsesterapi til parkinsons sygdom
CN117615768A (zh) * 2021-06-24 2024-02-27 韦斯特兰德特斯创新股份公司 用于帕金森病的nad增效疗法
CN118176006A (zh) * 2021-10-27 2024-06-11 益力舒健康公司 治疗更年期综合征的方法
EP4727544A2 (en) 2023-06-14 2026-04-22 Chromadex Inc. Nicotinamide riboside and derivatives thereof in intravenous formulations and methods of use thereof
CN116807985A (zh) * 2023-06-20 2023-09-29 风火轮(上海)生物科技有限公司 一种烟酰胺核糖组合物及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1964627B (zh) 2004-06-04 2011-10-19 华盛顿大学 治疗神经病变的方法和组合物
EP2805719A1 (en) 2005-03-30 2014-11-26 Glaxosmithkline LLC Nicotinamide riboside and analogues thereof
US20090069444A1 (en) 2007-09-07 2009-03-12 The United States Of America, As Represented By Th E Secretary Of Agriculture Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration
US20090163580A1 (en) * 2007-12-24 2009-06-25 Natrol, Inc. Anti-aging composition containing resveratrol and method of administration
WO2010095926A1 (en) * 2009-02-20 2010-08-26 N.V. Nutricia Use of reveratrol for preserving cognitive functioning
EP2445488B1 (en) 2009-06-22 2020-03-18 Indus Biotech Private Limited Process for obtaining purified pterostilbene and methods of use thereof
WO2011011721A2 (en) 2009-07-24 2011-01-27 Amazentis Sa Compounds, compositions and methods for protecting brain health in neurodegenerative disorders
US9439875B2 (en) 2011-05-11 2016-09-13 The United States Of America, As Represented By The Secretary Of Agriculture Anxiolytic effect of pterostilbene
EP2574339A1 (de) * 2011-09-27 2013-04-03 Johannes Huber Pharmazeutisches Präparat zur Behandlung von NADH-bedingten Erkrankungen
US20130149277A1 (en) 2011-12-13 2013-06-13 Cliffstar Llc Pterostilbene and pvp grape juice extract combination for treatment of metabolic, vascular, and neurodegenerative disorders
US20130296440A1 (en) 2012-05-01 2013-11-07 ChromaDex Inc. Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation
JP6509844B2 (ja) * 2013-10-30 2019-05-08 クロマデックス, インコーポレイテッドChromaDex, Inc. 皮膚症状の治療において局所使用されるニコチンアミドリボシド組成物
US10316054B2 (en) 2014-06-02 2019-06-11 Glaxosmithkline Intellectual Property (No. 2) Limited Preparation and use of crystalline beta-D-nicotinamide riboside
WO2016122832A1 (en) * 2015-01-30 2016-08-04 Natural Formulations Compositions, therapeutic and prophylactic methods for treatment of neurodegenerative diseases and brain injuries
WO2016149277A1 (en) * 2015-03-17 2016-09-22 Specialty Nutrition Group, Inc. Nutritional compositions to enhance mitochondrial energy production
JP7132907B2 (ja) 2016-08-22 2022-09-07 エリジウム・ヘルス・インコーポレイテッド ニコチンアミドリボシド及びプテロスチルベン組成物及び神経変性障害の治療方法

Also Published As

Publication number Publication date
AU2017316614A1 (en) 2019-03-21
EP3500267A4 (en) 2020-03-18
CN109982706A (zh) 2019-07-05
MX2019002211A (es) 2019-10-30
RU2019108100A3 (enExample) 2020-11-27
US20220143055A1 (en) 2022-05-12
US11998561B2 (en) 2024-06-04
US11260069B2 (en) 2022-03-01
RU2019108100A (ru) 2020-09-22
US20190201426A1 (en) 2019-07-04
ZA201901536B (en) 2024-06-26
JP7132907B2 (ja) 2022-09-07
EP3500267A1 (en) 2019-06-26
JP2019524856A (ja) 2019-09-05
CN115645432A (zh) 2023-01-31
WO2018039207A1 (en) 2018-03-01
CA3034673A1 (en) 2018-03-01
AU2017316614B2 (en) 2023-06-15
KR20190046895A (ko) 2019-05-07

Similar Documents

Publication Publication Date Title
ZA201901536B (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders
ZA202206806B (en) Benzooxazole derivatives as immunomodulators
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
EP4272834A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
ZA201800056B (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
BR112017007063A2 (pt) ?composições e métodos para o tratamento de insônia?
EP4289820A3 (en) Compounds for use in treating alzheimer's disease in apoe4+/+ patients
MX2019004859A (es) Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
BR112017002260A2 (pt) derivados de piperazina como moduladores do receptor x do fígado
CY1125113T1 (el) Συνθεσεις και μεθοδοι για χρηση στην αγωγη της ομοκυστινουριας
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
PT3302454T (pt) Composições para utilização no tratamento da doença de parkinson e distúrbios associados
MX380290B (es) Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos.
MX2022013283A (es) Composiciones para limpieza de colon y tratamiento de trastornos gastrointestinales.
IL265911A (en) Epilimod preparations and methods of using them in the treatment of Alzheimer's disease
WO2018013951A9 (en) Targeting adenosine a2a receptors for the treatment of levodopa-induced dyskinesias
EP3554496A4 (en) METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE
MY191993A (en) Use of isolated fractions of mastic gum for treating optic neuropathy
EP3634979A4 (en) COMPOSITIONS AND METHODS OF TREATING ALZHEIMER'S MORBUS
BR112017009599A2 (pt) composições contendo apoaequorina e métodos de uso das mesmas para tratar inflamação neuronal
ZA201806103B (en) Compositions and methods for the treatment of sinus disease and disorders
HK40013419A (en) Apilimod compositions and methods for using same in the treatment of alzheimer's disease
CO2019003858A2 (es) Formulaciones de cisteamina y derivados de cisteamina

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]